Drive Capital, a venture capital firm, and Aisling Capital, an investment firm, led a $90m Series C funding round in Forge Biologics. “Forge has grown tremendously over the last two years, hiring experienced talent and scaling the facility, technology, and client offerings according to their unique hybrid business model. We believe that Forge is becoming an established leader in gene therapy manufacturing, consistent with Drive Capital’s focus to build and support market-defining companies,” Molly Bonakdarpour, Drive Capital General Partner.